Designer drugs to inhibit hepatitis A virus

(PLOS) Structure-based drug design revealed that a compound previously investigated for the treatment of head-and-neck cancer could function as a lead compound for the development of drugs to treat hepatitis A virus infection, according to a study publishing April 30, 2019 in the open-access journal PLOS Biology by Dan Su of Sichuan University, Zihe Rao of Tsinghua University, Xiangxi Wang of the Chinese Academy of Sciences, and colleagues.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news